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Objectives: Transaortic left ventricular septal myectomy yields excellent results for
most severely symptomatic patients with hypertrophic obstructive cardiomyopathy.
However, associated anomalies of the mitral subvalvular apparatus may prevent
complete relief of obstruction, and mitral valve replacement has been advocated. We
reviewed our results of procedures designed to relieve obstruction with preservation
of the mitral valve.
Methods: Among 291 patients undergoing septal myectomy from 1975 to 2002, 56
(ages 2-77 years) had anomalous mitral subvalvular apparatus including anomalous
chordae (n  28) and papillary muscles with direct insertion into mitral leaflets (n
 13) or fusion to septum (n  31) or free wall (n  12); 82% of patients were in
New York Heart Association class III or IV. Operation included resection of
anomalous chordae (28 patients), relief of papillary muscle fusion (36 patients), and
extended septal myectomy, wider at the apex than the base.
Results: There were no early deaths and no patients required mitral valve replace-
ment. Mean peak pressure gradients decreased from 70  28 to 4.9  8.4 mm Hg
and mean mitral regurgitation grade decreased from 2.3 to 1.0 (P  .001). Mean
follow-up was 2.8  2.6 years. Freedom from reoperation at 4 years was 95%.
There were 3 late noncardiac deaths; 98% of patients were in New York Heart
Association class I or II.
Conclusions: Hypertrophic obstructive cardiomyopathy associated with anomalous
mitral papillary muscles or chordae can be successfully treated without mitral valve
replacement by surgical relief of the anomalies and an extended septal myectomy;
early mortality is low, obstruction and mitral regurgitation are significantly reduced,
and late results are excellent.
Hypertrophic cardiomyopathy is a primary genetic myocardial dis-ease.1 Its heterogeneity is well documented in terms of clinicalmanifestations, hemodynamic characteristics, anatomic morphol-ogy, and natural history.1,2 Many patients have variable degrees ofdynamic left ventricular outflow tract obstruction (LVOTO) dueto systolic anterior motion (SAM) of the anterior mitral leaflet.
SAM is also responsible for concomitant mitral regurgitation, which is typically
directed posterolaterally into the left atrium.3
Most patients’ symptoms are controlled medically, but 5% of all patients in
primary care settings and up to 30% in populations referred to large medical
centers have a marked outflow gradient at rest or with provocation associated
with severely limiting symptoms unresponsive to maximal medical therapy.4 For
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these patients, left ventricular septal myectomy, also
known as the Morrow procedure, has been the standard
therapeutic option for children and adults.5-11
Classical septal myectomy effectively abolishes
LVOTO, SAM, and associated mitral regurgitation and
yields excellent late results. However, some symptomatic
patients with hypertrophic obstructive cardiomyopathy
(HOCM) have associated anomalies of the mitral subvalvu-
lar apparatus that if unrecognized and untreated can lead to
intraoperative death or incomplete or only temporary relief
of obstruction.12,13 Perhaps the most important of these
anomalies is anomalous papillary muscle insertion directly
into the anterior mitral leaflet, an entity that has been well
documented by Klues and associates.12,13 Mitral valve re-
placement has been advocated by some as the best surgical
solution for this serious anomaly. Other anomalies of mitral
subvalvular apparatus include extensive fusion of papillary
muscles with the ventricular septum or left ventricular free
wall, abnormal chordae tendineae (false cords) that attach to
the ventricular septum or free wall, and accessory papillary
muscles, all of which may tether the mitral leaflets toward
the septum and produce LVOTO. Additional mechanisms
of dynamic LVOTO, which are not necessarily related to
papillary muscle anomalies, include midventricular obstruc-
tion secondary to severely hypertrophied papillary muscles
or other muscle bundles14 and anterior displacement of the
anterolateral papillary muscle.15
Increasing awareness of the importance of anomalies of
the mitral subvalvular apparatus and improved ability to
visualize subvalvular structures by means of optical mag-
nification and fiber-optic lighting have led to their increased
identification and successful surgical treatment.11-14,16 This
article reviews the early and late results of patients who
have undergone operation for HOCM associated with
anomalies of the mitral subvalvular apparatus.
Patient and Methods
Between April 1975 and August 2002, 291 patients underwent
operation for HOCM at the Mayo Clinic. In the early part of the
series, the diagnosis of HOCM was based on clinical evaluation
and cardiac catheterization. More recently, cardiac catheterization
has been supplanted by echocardiography and is performed only
when supplemental information is required. Examples include
evaluation of dynamic obstruction under monitored conditions in
symptomatic patients for whom satisfactory echocardiographic
pressure gradients cannot be obtained during exercise, or evalua-
tion of coronary arteries in patients at risk for coronary artery
disease. Indications for operation included patients with severe
symptoms unresponsive to or intolerant of optimal medical therapy
with left ventricular outflow tract (LVOT) pressure gradients
greater than or equal to 50 mm Hg (measured with Doppler
echocardiography either under resting conditions and/or with prov-
ocation, preferably utilizing physiologic exercise). Anomalies of
the mitral subvalvular mechanism were often suspected or con-
firmed preoperatively by echocardiography, but the exact anatom-
ical details were defined intraoperatively.14 Patients with com-
bined severe right ventricular outflow tract obstruction as well as
LVOTO who underwent biventricular septal resections were ex-
cluded from this review (n  9).
Regarding the overall series of 291 patients, early mortality was
0% for the 200 patients undergoing isolated septal myectomy and
1% (n  3) for the entire series, which included concomitant
cardiac procedures such as valve replacement and myocardial
revascularization.
Fifty-six of the 291 patients (19%) were found to have anom-
alous mitral subvalvular apparatus, and they form the cohort for
this review. There were 23 men and 33 women with ages ranging
from 2 to 77 years (mean 42  20, median 43). Patient demo-
graphics are summarized in Table 1. Eleven patients who had
undergone prior dual chamber pacemaker implantation had re-
ceived only temporary (n  6) or insignificant (n  5) relief of
symptoms and gradients. The mean interval between permanent
pacemaker implantation and septal myectomy was 4.1 2.5 years.
Three patients considered to be at high risk for sudden death had
undergone implantable cardioverter defibrillator (ICD) implanta-
tion elsewhere prior to septal myectomy. The indications for prior
implantation of ICD included history of cardiac arrest, ventricular
tachycardia, and strong family history of sudden deaths in 1 patient
each.
One patient (patient A) had previously undergone a classical
myectomy at age 5 years with significant reduction of LVOT
gradient and degree of mitral regurgitation, at which time anom-
alies of his subvalvular mechanism were not recognized. However,
he entered the cohort of this review when reoperation was neces-
sary 10 years later because of recurrent LVOTO and severe mitral
regurgitation.
Preoperatively, 82% (n  46) of the patients were New York
Heart Association (NYHA) class III or IV (Figure 1). Only 1
patient was asymptomatic, a 14-year-old boy who was observed to
have rapid progression of LVOTO and mitral regurgitation; his
peak systolic gradient was 93 mm Hg. Preoperative hemodynamic
and echocardiographic data are shown in Table 2.
TABLE 1. Patient demographics
Variables Number (%)





History of atrial fibrillation 11 (20)
History of ventricular tachycardia 3 (5)
Preoperative medications†
Beta-blocker 37 (66)
Calcium antagonist 28 (50)
Other antiarrhythmic agents 9 (16)
Prior dual chamber pacemaker 11 (20)
Prior ICD implant 3 (5)
HCM, Hypertropic cardiomyopathy; ICD, implantable cardioverter defibril-
lator.
*Some patients had more than 1 symptom.
†Some patients took more than 1 cardiac medication.
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It is possible to identify mitral apparatus anomalies such as direct
papillary muscle insertion into mitral valve with either transtho-
racic echocardiography at clinical evaluation or transesophageal
echocardiography in the operating room. Images obtained in the
parasternal long-axis or apical cross-sectional planes may suggest
that a papillary muscle and the mitral valve are contiguous by
virtue of a rigid (ie, nonflexible) motion pattern during the cardiac
cycle, no evidence of chordae interpositioned between papillary
muscle and mitral valve, and midventricular muscular apposition
between papillary muscle and ventricular septum during systole.
Usually, SAM is absent or mild without mitral-septal contact, and
the level of obstruction can be demonstrated with pulsed Doppler
to be midventricular. On occasion, SAM can be evident (even with
mitral-septal contact), presumably emanating from a free edge of
anterior mitral leaflet removed from the site of anomalous papil-
lary muscle insertion. It should be emphasized that clinical iden-
tification of mitral apparatus anomalies, particularly direct papil-
lary muscle insertion into mitral valve, may be exceedingly
difficult even for expert echocardiographers (including those
knowledgeable regarding hypertrophic cardiomyopathy), as it may
require nonstandard (off-center) cross-sectional imaging planes
not oriented through the midcavity of the left ventricle because
anomalous papillary muscles do not necessarily attach to the mitral
valve in the central portion of the leaflet. Anomalous chordae
tendineae within the LVOT, oriented in a variety of directions and
usually attaching to papillary muscles and ventricular septum, also
may sometimes be identifiable with echocardiography.
In this series, the diagnosis of anomalous papillary muscles was
first made by preoperative transthoracic echocardiography (n 
11), intraoperative transesophageal echocardiography (TEE) (n 
4), or direct inspection at the time of operation (n  30).
Current Surgical Techniques
Intraoperative TEE is performed after induction of general anes-
thesia, with particular attention to the cardiac anatomy, mitral
valve function, and thickness of the ventricular septum. Exposure
is gained through a median sternotomy and pressures are measured
in all 4 cardiac chambers and aorta. If the right ventricular pressure
is elevated, pulmonary arterial pressure is also measured to eval-
uate possible right ventricular outflow tract obstruction or pulmo-
nary hypertension. Standard cardiopulmonary bypass with moder-
ate hypothermia (28°C-32°C) is used and the left heart is vented.
Myocardial protection, especially important because of the severe
ventricular hypertrophy, is begun with a generous infusion of cold
blood cardioplegic solution into the aortic root followed by addi-
tional doses given selectively into the left and right coronary ostia
every 20 minutes. Topical cooling with ice-slush saline solution is
also applied, and an insulating pad is placed behind the left
ventricle during the more complex procedures. A transverse aor-
totomy is made, carried rightward toward the noncoronary sinus,
and retracted with pledgeted sutures. The aortic wall at the distal
valve commissures is suspended with pledgeted sutures attached to
the drapes or wound edges to maximize exposure of the hypertro-
phied septum and anterior mitral leaflet.
The classical portion of the resection is begun by making 2
parallel longitudinal incisions in the septum, the first beneath the
nadir of the right coronary cusp and the second beneath the
commissure between the right and the left coronary cusps. These
incisions are connected superiorly with a third incision 1.0 to 1.5
cm below the aortic valve, and a deep wedge of septal tissue is
resected (Figure 2, A). Care is taken to carry the incision apically
beyond the point of mitral-septal contact (marked by the fibrous
friction lesion; Figure 2, A). This classical resection is then ex-
tended in several ways, beginning with continued resection left-
ward toward the mitral valve annulus and apically to the bases of
TABLE 2. Hemodynamic and echocardiographic data
Premyectomy Postmyectomy P value
LVOT peak pressure gradient
(mm Hg)




70 28 4.9 8.4 .001
Median 66 1
Mean MR grade (TEE) 2.3 1.2 1.0 0.5 .001
None (0/4) 3 (5%) 8 (14%)
Trivial/mild (1/4) 16 (29%) 43 (77%)
Moderate (2/4) 18 (32%) 5 (9%)
Moderately severe (3/4) 5 (9%) 0 (0%)
Severe (4/4) 14 (25%) 0 (0%)
Mean AR grade (TEE) 0.33 0.52 0.42 0.50 NS
None (0/4) 41 (73%) 37 (66%)
Trivial/mild (1/4) 14 (25%) 19 (33%)
Moderate (2/4) 1 (2%) 0 (0%)
Moderately severe (3/4) 0 (0%) 0 (0%)
Severe (4/4) 0 (0%) 0 (0%)
Mean LVEF (%) (TTE) 74 5.7 72 6.7 NS
AR, Aortic regurgitation; LVEF, left ventricular ejection fraction; LVOT, left
ventricular outflow tract; MR, mitral regurgitation; TEE, intraoperative
transesophageal echocardiography; TTE, transthoracic echocardiography
preoperatively and at hospital discharge.
Figure 1. New York Heart Association functional classes preop-
eratively and at late follow-up.
Minakata et al Surgery for Congenital Heart Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 2 483
CH
D
the papillary muscles. The apical third of the right side of the
septum is then resected to obtain a much wider trough at the apex
than the base (a laboratory flasklike configuration as shown in
Figure 2, B). For midventricular obstruction due to hypertrophied
papillary muscles or muscle bundles, additional resection is made
around the bases of the papillary muscles. All areas of papillary
muscle fusion to the septum or ventricular free wall are divid-
ed,11,14-16 and anomalous chordal structures and fibrous attach-
ments of the mitral leaflets to the ventricular septum or free wall
are divided or excised. All abnormal chordae attached to the free
edge of the mitral leaflet are preserved to prevent flail leaflet. The
adequacy and distal extent of the resection are evaluated by direct
inspection and digital palpitation. After the patient is weaned from
cardiopulmonary bypass, pressures are remeasured in the left ven-
tricle and aorta and TEE evaluation is repeated.
Demographic and other patient-related data were obtained from
medical records. Follow-up information was obtained from subse-
quent clinic visits, written correspondence from local physicians,
and telephone interviews with patients or families.
The probability of survival and survivorship free of reoperation
were estimated by the Kaplan-Meier method. Patient survival
curves were compared with the expected curves of persons of the
same age and sex as derived from vital statistics for the west north
central region of the United States. The rank sum test was used to
compare continuous variables. Data were expressed as mean 
standard deviation. Early operative mortality was defined as death
occurring within 30 days of operation or at any time during the
index hospitalization. This study was approved by the Mayo Foun-
dation Institutional Review Board, and patients or families gave
informed consent.
Anomalies of Mitral Subvalvular Apparatus
The intraoperative findings of anomalies of mitral subvalvular
apparatus are listed in Table 3. In addition to the anomalies shown,
the papillary muscles were often severely hypertrophied, creating
additional obstruction at midventricular level. Anterior displace-
ment of the anterolateral papillary muscle was common.
Anomalous papillary muscles constituted the subset most likely
to create important LVOTO, especially those that inserted directly
into the mitral leaflets (Figure 2, B). The degree of fusion of
papillary muscles to the ventricular septum (Figure 2, B) or free
wall varied from fusion of the base only to fusion of the entire
length of the papillary muscle. A few patients had accessory
papillary muscles (Figure 3, A) or fibrous fusion of a portion of the
anterior mitral leaflet directly to the septum. These anomalies
appeared to play a role in augmenting LVOTO by restricting
mobility of the leaflets and/or tethering them toward the septum,
thus narrowing the LVOT.
False cords arising from 1 or both papillary muscles and
inserting into the ventricular septum or free wall were common
(Figure 3, A and B). When they were inspected in the relaxed heart,
in most cases it was not possible to determine whether or not they
contributed to the LVOTO. However, when they were encoun-
tered, they were resected or divided to improve mobility of the
papillary muscles.
Results
The mean cardiopulmonary bypass time was 85  32 min-
utes and the mean aortic crossclamp time was 58  15
minutes. Concomitant procedures performed in 9 patients
Figure 2. A (left), Classic left ventricular septal myectomy for hypertrophic obstructive cardiomyopathy. B (right),
Extended left ventricular septal myectomy for anomalous papillary muscle with direct insertion into anterior mitral
leaflet and also fusion to the septum.
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(all for preexisting conditions) included mitral valve repair
(n  2), resection of additional discrete membranous sub-
aortic stenosis (n  2), aortic valve repair (n  2), aortic
valve replacement (n 1), radical pericardiectomy (n 1),
and repair of Ebstein anomaly (n 1). Mitral valve replace-
ment was not necessary in any patient.
Means of intraoperative direct measurements of peak
systolic LVOT gradients pre- and postmyectomy are shown
in Table 2; the decrease in mean gradient was highly sig-
nificant. Intraoperative assessment of mitral regurgitation
by TEE pre- and postmyectomy showed a concomitant
highly significant reduction of mean echocardiographic
grade (Table 2). There was no significant change in aortic
regurgitation grade or left ventricular ejection fraction.
There were no early deaths. Early morbidity included
atrial fibrillation necessitating antiarrhythmic drugs with or
without cardioversion (n  11), need for permanent pace-
maker (n  3) (2 of the 3 had isolated septal myectomy; 1
of the 2 had return of sinus rhythm on follow-up), and
temporary neurological events (n  2). Seven patients who
were considered to be at high risk for sudden death because
of a strong family history of sudden death or nonsustained
ventricular tachycardia on 24-hour electrocardiographic
monitoring underwent elective placement of an ICD. Com-
parisons of mean transthoracic echocardiographic estimates
of peak systolic LVOT gradients preoperatively and prior to
hospital discharge showed a highly significant reduction at
discharge (Table 2).
Follow-up obtained in 54 of 56 patients (96%) ranged
from 1 month to 13 years (mean 2.8  2.6 years). There
were 3 late deaths, all noncardiac, from chronic renal failure
(n  2, ages 42 and 82 years) and stroke (n  1, age 76
years). Probability of survival was 98% and 91 % at 1 and
4 years, respectively (Figure 4). The difference between
observed survival and expected survival was not statistically
significant (P  .08). Of the 51 late survivors followed,
98% were in NYHA class I or II (Figure 1).
One 2-year-old patient (patient B), whose anomalies of
mitral subvalvular apparatus were recognized at operation,
subsequently required a second cardiac operation. At the
first operation, multiple attachments of the posteromedial
papillary muscle to the ventricular septum were noted, and
midventricular obstruction was present. She also had severe
mitral valve regurgitation from posterior leaflet prolapse. A
planned extended myectomy was limited somewhat by the
small size of aorta and restricted access to the subvalvular
area. She improved postoperatively but subsequently rede-
veloped severe mitral regurgitation and a midventricular
gradient (34 mm Hg). Reoperation at age 5 included mitral
valve repair (annuloplasty and posterior leaflet plication)
and an extended midventricular resection; the LVOT gra-
dient was reduced to 5 mm Hg. She is currently doing well
and in NYHA class I.
Three patients underwent late ICD implantation because
of sudden death of a family member (n  2) or syncope (n
 1).
Survivorship free of cardiac reoperation at 1 and 4 years
was 100% and 95%, respectively.
Discussion
Hypertrophic cardiomyopathy is characterized by inappro-
priate hypertrophy of the myocardium and is associated
with various clinical presentations ranging from complete
absence of symptoms to sudden, unexpected death. There is
a subgroup of patients who develop severe limiting symp-
toms of dyspnea, angina, or syncope, or a combination of
these, due primarily to dynamic obstruction of the LVOT
and associated mitral regurgitation. The established medical
therapy for patients with HOCM has been a trial of large
doses of beta-blockers, calcium channel antagonists, or di-
sopyramide, either alone or in combination. Operation has
been the gold standard therapy for those severely symptom-
atic patients with fixed or inducible gradients who are
intolerant of these medications or unresponsive to them.2,4
Surgical approaches for HOCM were first initiated in the
late 1960s. The first surgical procedures proposed for relief
of LVOTO were simple incision in the basal septal bulge,
sometimes deepened with the surgeon’s finger (myotomy),
or excision of obstructing muscle under direct vision (my-
ectomy).5 Historically, surgical exposure of the septum has
been obtained through the aorta, left ventricle, right ventri-
cle, or left atrium; the transaortic approach is now preferred
by most surgeons. To preserve conduction tissue in the
septum, the surgeon can remove tissue only in a specific
location in the septum. Decrease or abolition of the LVOT
gradient is accomplished not only by physical enlargement
of the outflow tract but also by interruption of the patho-
physiological events (primarily SAM) that cause the out-
flow gradient. Complete relief of LVOTO by septal myec-
tomy results in correction of mitral regurgitation caused by
SAM. Any residual mitral regurgitation due to ruptured
chordae, mitral valve prolapse, or annular dilatation can
usually be corrected by mitral valve repair and annulo-
plasty.17
TABLE 3. Intraoperative findings of anomalies of mitral
subvalvular apparatus*
Anomalous papillary muscles 45
Direct insertion into anterior mitral leaflet 13
Fusion to ventricular septum 31
Fusion to left ventricular free wall 12
Accessory papillary muscle 2
Anomalous chordae tendineae (false cords) 28
Fusion of mitral leaflet to septum 3
*Some patients had more than 1 anomaly.
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Replacement of the mitral valve with a low-profile mitral
valve prosthesis—once proposed as an alternative to septal
myectomy—also reduces the left ventricular outflow gradi-
ent and improves symptoms.18 The major disadvantage of
this procedure is that 1 disease process is replaced with
others such as problems of durability, infection, thrombo-
embolism, and anticoagulation, which are associated with
prosthetic valves. In general, mitral valve replacement is
now reserved for significant mitral regurgitation in patients
with primary mitral valve disease unsuitable for valve re-
pair.
Papillary muscle anomalies are recognized with increas-
ing frequency as causing or contributing to dynamic sub-
aortic obstruction, usually but not always associated with
SAM and mitral regurgitation, in some patients.4,11-14,16 In
1 report, an analysis of 78 mitral valves excised from
patients undergoing operation for HOCM showed that 10
(13%) had anomalous insertion of 1 or both left ventricular
Figure 3. A (left), Accessory papillary muscle arising from the anterior free wall with chordal attachments to the
mitral leaflet and free wall. B (right), Anomalous chordae tendineae arising from a papillary muscle and inserting
into the septum.
Figure 4. Probability of patient survival compared with expected survival of persons of the same age and sex (P
 .08).
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papillary muscles directly into the anterior mitral leaflet.13 If
unrecognized and untreated, these anomalies can cause in-
traoperative death or incomplete or only temporary relief of
obstruction.
These problems are exemplified by the 2 cases described
in this report. Patient A’s anomalies of mitral subvalvular
apparatus were not recognized at the time of classical my-
ectomy and were largely responsible for recurrence of se-
vere LVOTO and mitral regurgitation, which necessitated
reoperation 10 years later. Anomalies of subvalvular appa-
ratus in patient B (age 2 years) were recognized at opera-
tion, but relief of the anomalies was compromised by the
small size of aorta and limited visibility of the midventricu-
lar region. Reoperation was required 3 years later for com-
plete relief of LVOTO and mitral valve repair.
Key to recognition of subvalvular anomalies is excellent
intraoperative exposure, strong lighting with a fiber-optic
headlight, and magnification with optical loupes, combined
with a quiet, dry field. Elevation of the aortic valve com-
missures by sutures attached to the wound edges or drapes
is very helpful in improving exposure, especially in mas-
sively thickened hearts that lie transversely in the chest. In
most cases, the subvalvular region is not well seen, or not
seen at all, until the classical myectomy is completed.
Visualization of the subvalvular region improves as the
several additional resections of an extended myectomy are
performed. Resection at midventricular level is facilitated
by use of long rongeurs or biopsy forceps. Sharp-toothed
rake retractors aid retraction and resection of the septal
bulge and the apical third of the septum on the right side of
the septal trough. In our experience, the latter is not accom-
panied by an increased incidence of permanent complete
heart block, and it allows more complete midventricular
resection. Additionally, it more consistently provides absent
postmyectomy gradients and absent chordal SAM.
The mechanism of SAM is controversial and concepts
include the Venturi (pull) effect19,20 and a drag (push)
effect.21,22 Whatever the relative roles these mechanism
may play in creating dynamic LVOTO in HOCM, the
obstruction and associated mitral regurgitation are relieved
by classical septal myectomy in most patients. However,
when associated anomalies of mitral subvalvular apparatus
are present, additional measures may be required.
In conclusion, symptomatic patients with HOCM asso-
ciated with anomalous papillary muscles or chordae can be
successfully treated without mitral valve replacement by
surgical relief of the anomalies and an extended septal
myectomy; early mortality is low, LVOTO and mitral re-
gurgitation are significantly reduced, and late results are
excellent.
We thank the Mayo Clinic Division of Biostatistics for statis-
tical support and Judy K. Lenoch for advice and assistance with
data collection and analysis.
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Discussion
Dr William G. Williams (Toronto, Ontario, Canada). I appre-
ciate the privilege of discussing Dr Dearani’s excellent presenta-
tion. He has highlighted an important subset of hypertrophic car-
diomyopathy patients in whom there was an uncommon but
important mechanism of obstruction.
I would like to take this opportunity also to express my admi-
ration for the senior author, Dr Gordon Danielson. Throughout his
distinguished career at the Mayo Clinic, Dr Danielson has pro-
vided exemplary patient care while contributing his considerable
intellectual skills in solving many problems in congenital heart
surgery. He has established surgical myectomy as the gold stan-
dard for treatment of obstructive form of hypertrophic cardiomy-
opathy.
Hypertrophic cardiomyopathy affects as many as 1 person in
500 in the general population. Most patients referred for surgery
have the obstructive form of the disease. Typically the obstruction
is in the outlet, though it may be at midventricular or apical level.
Outlet obstruction is associated with systolic anterior motion of
the mitral valve, and this SAM increases the severity of the
obstruction and causes mitral regurgitation. Successful surgical
myectomy relieves the obstruction and almost invariably improves
or resolves the mitral regurgitation.
Mitral valve repair or replacement is indicated only when the
mitral regurgitation is independent of the obstruction, in which
case it usually precedes the SAM septal contact. In our own
myectomy experience for patients with hypertrophic cardiomyop-
athy, among 379 patients, mitral valve repair was required only in
11 and replacement in 2 patients.
Dr Dearani and his colleagues have demonstrated that a subset
of patients with mitral valve anomalies can be managed success-
fully with a more extensive modified myectomy, and repair or
replacement of the mitral valve is unnecessary. This subset of
patients is particularly important to identify, as their obstruction
may not be associated with the SAM.
Preoperative recognition of the papillary muscle anomalies
they describe is especially important in the current era of enthu-
siasm for alcohol ablation by our interventional colleagues because
successful alcohol ablation unlikely.
Dr Dearani stressed the intraoperative identification of this
anomaly. My first question is, can this mechanism of obstruction
be reliably diagnosed preoperatively? In the 1991 work by Klues,
Roberts, and Maron, it was recognized only in 1 of the 10 preop-
eratively.
Although we are confident that surgical myectomy for patients
with outlet obstruction is highly efficacious, I am less confident
that surgical treatment of isolated midventricular obstruction is
beneficial. Did any of these patients have isolated midventricular
obstruction, and in that situation would you recommend myec-
tomy?
Because the modified extended myectomy you describe has
been successful without increasing the incidence of AV block,
would the authors recommend this modified myectomy for all
patients in whom the outlet obstruction extends to the midven-
tricular level, or indeed in all patients with obstructive hypertro-
phic cardiomyopathy?
I congratulate you for clarifying both the identification and
management of this important subset of patients with obstructive
hypertrophic cardiomyopathy.
Dr Dearani. Thank you, Dr Williams, for your kind comments.
It is possible to identify anomalies of the mitral subvalvular
apparatus such as direct papillary muscle insertion into the mitral
valve with either preoperative transthoracic echocardiography or
intraoperative transesophageal echocardiography. Images obtained
in the parasternal long-axis or apical cross-sectional planes may
suggest that a papillary muscle and the mitral valve are contiguous,
without evidence of chordae between the head of the papillary
muscle and the mitral valve. In addition, there may be fusion of the
papillary muscle to the ventricular septum. Systolic anterior mo-
tion is often absent or mild and the level of obstruction is usually
at the midventricular level. It should be noted, however, that
identification of these anomalies of the mitral subvalvular appara-
tus can be difficult even for experienced echocardiographers.
Many of the patients in this series had midventricular obstruc-
tion. We are able to perform an extensive resection at the midven-
tricular level with our current techniques. Consequently, we do
advise left ventricular septal myectomy when isolated midven-
tricular obstruction is identified on echocardiographic studies. We
are currently examining the results of patients who have undergone
myectomy for isolated midventricular obstruction.
We have gained experience now with more than 700 patients
who have undergone myectomy over the last 3 decades. Our
technique of septal myectomy has evolved from the classic Mor-
row myectomy to a more extended myectomy. This includes
resection apically to the bases of the papillary muscles and resec-
tion leftward back toward the mitral valve. The apical third of the
right side of the septum is then resected, effectively making a
much wider trough at the apex than the base. The base of the
resected area is then deepened with a rongeur. In general, we
perform the extended myectomy in all patients undergoing oper-
ation for obstructive hypertrophic cardiomyopathy.
When an abnormal mitral subvalvular apparatus is present, we
divide all attachments that exist between the lateral edge of the
anterior leaflet and septum and divide all attachments between the
papillary muscle(s) and septum. It is important to maintain intact
all chordal attachments to the leading edge of the anterior leaflet.
The presence of a direct papillary muscle insertion into the anterior
mitral leaflet is often accompanied by fusion of the papillary
muscle to the septum. Surgical myectomy is performed in the
extended fashion and in addition, the papillary muscle is incised of
the septum down to its base.
Dr Richard A. Jonas (Boston, Mass). Joe, this is a 27-year
series with 292 patients, but your mean follow-up is 2.8 years, and
yet you state that your follow-up was 96% complete. Can you
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clarify for us whether this was a cross-sectional follow-up, which
is really what would be required to know whether this approach
was successful over the long term? Do you have a time-related
sense or a time-related analysis as to the risk of recurrent outflow
tract obstruction or mitral valve problem? Because your practice,
like ours, is a referral practice, many of these patients come from
cardiologists around the country and around the world, and there is
a tendency if there is a recurrence for parents to say, “We went to
the Mayo Clinic, and now the problem has come back. We don’t
want to go back there. We want to go somewhere else.” So I’m just
a little bit concerned if this is not a cross-sectional follow-up that
you may be missing quite a few recurrences.
Dr Dearani. All the patients but 2 had follow-up within 1 year
of the end of the study period (August 2002). Although this is a
review of 25 years’ experience of our surgical series, we first
recognized this anomaly in 1989. We modified our surgical tech-
nique in the mid-1990s to treat this subset of patients. Thus, we
found most of the patients with these anomalies very recently. In
fact, 32 patients (57%) were operated on after 2000. This explains
the mean follow-up of only 2.8 years.
Dr Constantine Mavroudis (Chicago, Ill). Joe, that was a beau-
tiful presentation. I have 3 questions, mostly relating to the technical
aspects of exposure. The first one, though, is not about exposure.
Is this the largest series of its kind in the literature of abnormal
papillary muscles that has been identified? Is that accurate?
Dr Dearani. Yes.
Dr C. Mavroudis. It is the largest?
Dr Dearani. Yes.
Dr C. Mavroudis. And then the next question. Occasionally I
perform a transection of the aorta to expose the aorta and look
directly down into the left ventricular outflow tract. I wonder if
that’s what you do, or how do you expose the aorta in difficult or
small cases?
And the last question I want to ask you is, do you use any
retractors that are mounted on the side and so forth, so you can get
an unobstructed view without anyone moving anything to look at
what you’re doing?
Dr Dearani. Yes. There are many maneuvers that we utilize
to facilitate a satisfactory, extensive myectomy. A transverse
aortotomy is made, carried rightward toward the noncoronary
sinus and down to the aortic annulus. The aortic valve commis-
sures are suspended with pledgeted sutures to maximize expo-
sure of the hypertrophied septum and anterior mitral leaflet.
Inspection of the anatomy is performed with identification of
the line of apposition of the anterior mitral leaflet to the septum
(friction lesion). Optimal visualization of the ventricular sep-
tum is facilitated by posterior displacement of the left ventricle
with a sponge forceps. In addition, a small rake retractor can be
used to engage the distal septum so that it can be pulled
cephalad toward the aortic annulus. A small vein retractor is
used to engage the superior aspect of the initial trough. Gentle
lateral retraction is performed with this retractor and at the same
time it protects the aortic valve from injury. A small cherry tip
sucker placed through the aortotomy is used to retract the
anterior mitral leaflet and chordae posteriorly away from the
septum while performing the myectomy so to avoid injury to
these structures. We only use handheld retractors with gentle
retraction in various directions to facilitate exposure during the
course of the myectomy.
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